SCHEMBL22945019

SCHEMBL22945019

C=CCC1(CNC(=O)OC(C)(C)C)CCCCC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.39
HCRTR2 O43614 1/20 0.37
TDP1 Q9NUW8 1/20 0.36
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
GAA P10253 1/20 0.34
CA12 O43570 3/20 0.33
CA2 P00918 3/20 0.33
CA1 P00915 2/20 0.33
CA9 Q16790 2/20 0.33
CA14 Q9ULX7 1/20 0.33
P2RX7 Q99572 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.32
DRD2 P14416 1/20 0.32
ALDH1A1 P00352 2/20 0.32
TSHR P16473 1/20 0.32
CTSK P43235 2/20 0.32
MAOA P21397 1/20 0.32
MAOB P27338 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23477736 0.99 HCRTR2 (0.38) EPHX1HCRTR2TDP1MEN1KMT2A
SCHEMBL29043368 0.96 HCRTR2 (0.38) EPHX1HCRTR2TDP1MEN1KMT2A
SCHEMBL23477886 0.93 HCRTR2 (0.39) EPHX1HCRTR2TDP1MEN1KMT2A
SCHEMBL14104233 0.87 EPHX1 (0.43) EPHX1HCRTR2TDP1MEN1KMT2A
SCHEMBL21607436 0.82 TDP1 (0.42) EPHX1HCRTR2TDP1MEN1KMT2A
SCHEMBL4780567 0.82 EPHX1 (0.42) EPHX1HCRTR2TDP1MEN1KMT2A
SCHEMBL29132498 0.82 TDP1 (0.41) EPHX1TDP1MEN1KMT2AGAA
SCHEMBL7611276 0.80 TDP1 (0.44) EPHX1HCRTR2TDP1MEN1KMT2A
SCHEMBL1076767 0.79 ALDH1A1 (0.45) EPHX1HCRTR2TDP1MEN1KMT2A
SCHEMBL3827875 0.78 EPHX1 (0.40) EPHX1HCRTR2TDP1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12528767-B2 HDAC6 inhibitors and uses thereof EIKONIZO THERAPEUTICS, INC. (US) 2026-01-20 US disclosed
US-20220281814-A1 HDAC6 INHIBITORS AND USES THEREOF EIKONIZO THERAPEUTICS, INC. (US) 2022-09-08 US disclosed
CN-114727974-A HDAC6 inhibitors and uses thereof 艾科尼佐治疗股份有限公司 2022-07-08 CN disclosed
EP-4003319-A2 HDAC6 INHIBITORS AND USES THEREOF Eikonizo Therapeutics, Inc. (US) 2022-06-01 EP disclosed
WO-2021021979-A2 HDAC6 INHIBITORS AND USES THEREOF EIKONIZO THERAPAPEUTICS, INC. (US) 2021-02-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220281814-A1 HDAC6 INHIBITORS AND USES THEREOF HDAC6, HDAC1, HDAC5 EPHX1 4295/4885HCRTR2 3514/4885TDP1 1112/4885
US-12528767-B2 HDAC6 inhibitors and uses thereof HDAC6, HDAC1, HDAC11 EPHX1 4807/4885HCRTR2 1153/4885TDP1 1617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.